At Highfield Communication we pride ourselves on building strong enduring relationships with the clinical and scientific experts that are integral to the success of your medical communication ...

DANIELS HUDSPETH is a new kind of healthcare brand consultancy: one that recognises that yesterday’s marketing models are no longer applicable. Today’s challenging marketing realities mean that ...

Rock Unlimited: Solid science. Fluid thinking. Lasting change.

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a global scale. We also syndicate our video library in ...

Rapport Events Ltd We are a people activation agency. We use creativity to inspire positive change in both people and organisation they represent. We do this through; Events, Experiential, Content, ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed ...

Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative ...

The World Health Organization (WHO) has declared the climate crisis one of the biggest global threats to human health. It currently estimates that one in four deaths can be attributed to preventable ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...